(1)
DURHAM, NC / ACCESSWIRE / May 19, 2021 / Baebies, a growth-stage company developing innovative products to enable early disease detection and multifunctional diagnostics for syndromic testing, was recently awarded $2.7 million in a Phase IIB SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). This award supports validation, clinical evaluation, and FDA submission of a rapid test panel for near-patient heparin monitoring. This project is a continuation of a long-standing collaboration with Boston Children s Hospital to develop a low blood volume platform for heparin monitoring particularly for neonates and pediatric patients.
Heparin is an anticoagulant prescribed to patients at high risk for thrombosis or who are being treated for conditions requiring anti-coagulant therapy such as those with congenital heart defects or other hospitalized patients. A patient who undergoes cardiac surgery will invariably be put on hep
Baebies Awarded $2.7 Million NIH Grant for Rapid, Near-patient Heparin Monitoring Requiring Low Sample Volume
ACCESSWIRE
20 May 2021, 02:55 GMT+10
DURHAM, NC / ACCESSWIRE / May 19, 2021 /Baebies, a growth-stage company developing innovative products to enable early disease detection and multifunctional diagnostics for syndromic testing, was recently awarded $2.7 million in a Phase IIB SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). This award supports validation, clinical evaluation, and FDA submission of a rapid test panel for near-patient heparin monitoring. This project is a continuation of a long-standing collaboration with Boston Children s Hospital to develop a low blood volume platform for heparin monitoring particularly for neonates and pediatric patients.
/ April 20, 2021 /
Baebies, a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, announced today that CARB-X has awarded the company up to $11.6 million in non-dilutive funding. This funding will support the development of a near-patient and rapid diagnostic platform for sepsis - specially focused on addressing the unique needs of neonatal and pediatric populations.
The CARB-X award consists of $3.9 million in initial funding with up to $7.7 million of milestone-based funding. CARB-X, a global non-profit partnership, provides funding and support for projects that target drug-resistant bacteria deemed Serious or Urgent on the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistant Threats list or Critical or High on the World Health Organization s Priority Bacterial Pathogens list.
Baebies Awarded up to $11 6 Million from CARB-X for the Development of a Diagnostic Platform with Rapid Results for Sepsis phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
San Antonio hospital on North Side earns designation as advanced trauma center
FacebookTwitterEmail
Vehicles are lined up at Methodist Hospital | Stone Oak for a “Park and Pray” event on Tuesday, April 7, 2020. The event, meant to encourage the hospital’s health workers during the coronavirus pandemic, was organized by ONE, a non-profit ministry. Ministers led people in prayer through a teleconference call. The hospital recently received a designation as a Level III trauma center.Billy Calzada /San Antonio Express-News
The state has designated Methodist Hospital | Stone Oak a Level III advanced trauma center making it one of 17 trauma facilities in San Antonio.